Autolus Therapeutics (AUTL) Change in Accured Expenses (2018 - 2023)

Autolus Therapeutics (AUTL) has 6 years of Change in Accured Expenses data on file, last reported at $31.4 million in Q3 2023.

• For the quarter ending Q3 2023, Change in Accured Expenses rose 722.75% year-over-year to $31.4 million; the trailing twelve-month figure through Sep 2023 stood at $31.4 million (up 722.75% YoY), and the FY2022 full-year result was $40.8 million, up 72.38% from the prior year.
• Change in Accured Expenses for Q3 2023 stood at $31.4 million, up from $31.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $40.8 million in Q4 2022 and bottomed at -$370000.0 in Q1 2019.
• The 5-year median for Change in Accured Expenses is $24.5 million (2022), against an average of $22.5 million.
• The widest annual swing landed in 2021, when Change in Accured Expenses surged 6937.4%; it then slumped 86.68% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $21.4 million in 2019, then advanced by 29.83% to $27.8 million in 2020, then declined by 14.81% to $23.7 million in 2021, then soared by 72.38% to $40.8 million in 2022, then dropped by 23.06% to $31.4 million in 2023.
• The last three Change in Accured Expenses figures came in at $31.4 million (Q3 2023), $31.0 million (Q2 2023), and $34.5 million (Q1 2023), per Business Quant data.

Peer Comparison